Evidence mapPaperPMID 41568128Full record

ReviewJournal of metabolic and bariatric surgery2025

Medication Adjustment After Bariatric and Metabolic Surgery: A Review of Current Evidence and Clinical Practice Trends.

Ji-Hyeon Park, Sojung Kim, Ho Seok Seo, Kyo Young Song, Han Hong Lee

Abstract readReview
In one paragraph

Review in Journal of metabolic and bariatric surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ji-Hyeon ParkDivision of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-6811-8895
Sojung KimDivision of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-5030-2918
Ho Seok SeoDivision of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-3606-6074
Kyo Young SongDivision of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-5840-1638
Han Hong LeeDivision of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-7541-8490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bariatric and metabolic surgery (BMS) is the most effective treatment for severe obesity and its related comorbidities. Rapid metabolic improvement following surgery frequently leads to the reduction or discontinuation of medications for obesity-related comorbidities. However, there are no established guidelines regarding timing or criteria for dose adjustment. A narrative review examined major clinical trials, meta-analyses, and society guidelines relevant to BMS. Evidence from previous and recent studies was synthesized to summarize pharmacokinetic alterations, disease-specific medication adjustments, and long-term deprescription patterns following BMS. Postoperative anatomical changes-including reduced gastric surface area, intestinal bypass, and altered acidity-affect the absorption of many oral drugs, requiring early dose adjustment. For type 2 diabetes mellitus, patients using <30 units/day of basal insulin can discontinue insulin after surgery, whereas those using ≥30 units/day typically require a 50-80% dose reduction. Most patients taking a single oral hypoglycemic agent may stop medication, while metformin monotherapy is recommended when glycated hemoglobin (HbA1c) <9% and dual therapy when HbA1c ≥9%. In hypertension, discontinuation of one antihypertensive drug usually results in approximate 10 mmHg reduction in systolic blood pressure. Diuretics should be withheld for the first 2 weeks postoperatively to prevent dehydration and excessive volume loss. For dyslipidemia, lipid-lowering agents are adjusted according to postoperative lipid profile changes and restarted if necessary. In psychiatric disorders, early resumption of preoperative medications is recommended to prevent withdrawal symptoms or relapse. BMS enables early medication reduction across comorbidities, yet individualized pharmacologic management remains essential to sustain metabolic improvement and long-term disease control.

Indexed as

Bariatric surgeryDiabetes mellitusHypertensionPharmacokineticsPostoperative care

Identifiers

PMID41568128
PMCPMC12817811

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.